-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓BörseISIN INE700A01033
ISIN INE700A01033
ETFs die in JUBILANT LIFE SCIENCES LTD investieren
Dir gefallen die Informationen zu JUBILANT LIFE SCIENCES LTD?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu JUBILANT LIFE SCIENCES LTD?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu JUBILANT LIFE SCIENCES LTD?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu JUBILANT LIFE SCIENCES LTD?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
26 News & Informationen zur JUBILANT LIFE SCIENCES LTD Aktie
Rakesh Jhunjhunwala buys 25 lakh shares of this pharma firm, stock rises 4%
Jubilant Pharmova share gained over 4 per cent in early trade today after ace investor Rakesh Jhunjhunwala bought 25 lakh shares of the company. The mid cap stock touched an intraday high of Rs 639.45, rising 4.51% against previous close of Rs 611.85 on BSE.
Jubilant Pharmova up 2%, gains focus after Jhunjhunwala buys 20 lakh shares
Rare Enterprises sold 40.25 lakh equity shares at same price
Stocks that will see action today
Focus on Ujjivan SFB, Alicon Castalloy, Alicon Castalloy, Max Healthcare Institute, Future Retail
Trade setup for Thursday: Top 15 things to know before Opening Bell
Rajesh Palviya of Axis Securities feels on the downside, any violation of an intraday support zone of 16,600 levels may cause profit booking towards 16,500-16,400 levels.
NIIT Q1 results: Net profit rises 78% to Rs 51 crore
Its revenue increased 49 per cent to Rs 301 crore in the April-June 2021 quarter, from Rs 201.8 crore in the year-ago period, it added.
Small & Midcap Mantra: Upper Bollinger Band on charts of this specialty chemical company suggests fresh highs in offing
Jubilant Ingrevia has been in an uptrend since it got listed on the exchanges. It hit a record high of Rs 671 on July 22. A recent breakout suggests a further upside up to Rs 730-750 in the next 3-6 months.
Wait for 16K on Nifty continues, 10 technical trading ideas for next 3-4 weeks
If Nifty has to reach and surpass the magical figure of 16000, the banking certainly plays a vital role, suggest experts.
Jubilant Pharmo Consolidated June 2021 Net Sales at Rs 1,634.65 crore, down 13.64% Y-o-Y
Stocks to watch: RIL, ITC, Tata Motors, ICICI Bank, JSW Steel, YES Bank
Read more about Stocks to watch: RIL, ITC, Tata Motors, ICICI Bank, JSW Steel, YES Bank on Business Standard. Cipla is recalling 7,228 bottles of Solifenacin Succinate tablets in the US market due to manufacturing issues
Jubilant Pharmova Q1 Review – Radiopharma On A Gradual Recovery Path: Motilal Oswal
Jubilant Pharmova Ltd. delivered in line earnings, despite a better than expected revenue in Q1FY22.
The Covid-19 related business led to a strong y-o-y revenue growth. reduced number of lung procedures in the radiopharma segment, increased price erosion in the Sartans portfolio, and price erosion in the base portfolio in the generics segment led to lower-than-expected profitability We have reduced Jubilant Pharmova's FY22E/FY23E EPS estimate by 14% each to factor in: delay in potential products on account of the import alert at Roorkee,
Jubilant Pharmova posts Q1 net profit of Rs 160 crore
The company had posted a net profit of Rs 35.39 crore for the year-ago period, Jubilant Pharmova said in a regulatory filing
Jubilant Pharmova Q1 results: Co posts net profit of Rs 160 crore
Revenue from continuing operations stood at Rs 1,634.65 crore in the quarter under review. It was Rs 1,156.07 crore in the same period a year ago, it added.
Jubilant Pharmova profit jumps 350% to Rs 160 crore in Q1FY22
The net profit jump was led by gradual recovery in specialty radiopharmaceutical business hit by COVID-19, traction in contract manufacturing and generics segment performing well on COVID antiviral drug Remdesivir sales.
Global pharmaceutical contract manufacturing market size to record 7.5% CAGR through 2027
The latest business intelligence report on ‘global pharmaceutical contract manufacturing market’ offers an accurate picture of the industry’s growth…
Jubilant Pharmova – U.S. FDA Issues Import Alert On Roorkee Facility: ICICI Securities
Jubilant Pharmova announced that it has received import alert from U.S. Food and Drug Administration for its Roorkee facility. U.S. FDA re-inspected the plant in March 2021 and subsequently has issued an import alert to it. It is a solid dosage formulations manufacturing facility with supplies to U.S., ROW markets.
Gainers & Losers: 10 stocks that moved most on July 15
The BSE midcap and smallcap indices closed 0.31 percent and 0.43 percent higher, respectively
Global Genetic Toxicology Testing Market is Estimated to Grow at a CAGR of 10.0% from 2021 to 2030
Browse key industry insights spread across 155 pages with 85 market data tables and 41 figures & charts from the report, “Global Genetic Toxicology Testing…
Two IPOs to hit market next week; to raise over Rs 2,500 cr cumulatively
This comes after five companies Shyam Metalics and Energy, Sona BLW Precision Forgings (Sona Comstar), Krishna Institute of Medical Sciences, Dodla Dairy and Indian Pesticides launched their initial public offers (IPOs) last month. These firms collectively raised Rs 9,923 crore through public issues.
30 IPOs coming in next six months to leave you spoilt for choice
Analysts are positive on the IPO market momentum, as the secondary market indices trade near their lifetime highs. Also, retail participation, chasing listing gains, has also gone up during this period.
Jubilant Pharmova share price: Buy Jubilant Pharmova, target price Rs 960: Motilal Oswal
Jubilant Pharmova Ltd., incorporated in the year 1978, is a Mid Cap company (having a market cap of Rs 11743.00 Crore) operating in Pharmaceuticals sector.
Jubilant Pharmova – Demand Prospects Favourable; Execution Remains Key: Motilal Oswal
Jubilant Pharmova Ltd. hosted an investor/analyst meet to discuss the business and strategic initiatives in key business segments.
With the Covid-19 disruption behind in key markets, the company expects radio pharma sales to recover in H2 FY22, supplemented by incremental sales from Ruby-Fill in Europe.
The company is proactively undertaking expansions at Montreal and Spokane to be able to cater to future demand in the CDMO space.
Its novel chemical entities assets are expected to enter clinics within the next six to nine months
Contract Development and Manufacturing Organization Industry in APAC to 2030 – Key Drivers, Restraints and Challenges
DUBLIN, Jan. 13, 2021 /PRNewswire/ — The 'Asia-Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030…
Contract Development And Manufacturing Organization Industry In APAC To 2030 – Key Drivers, Restraints And Challenges
DUBLIN, Jan. 13, 2021 /PRNewswire/ — The “Asia-Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category,
Global Active Pharmaceutical Ingredients Market Report 2020: Data from 2018, 2019, Estimates for 2020 and Projection of CAGR through 2025
DUBLIN, Jan. 8, 2021 /PRNewswire/ — The 'Active Pharmaceutical Ingredients: Global Markets' report has been added to ResearchAndMarkets.com's off…
Global Active Pharmaceutical Ingredients Markets Report 2020 with Profiles of Actavis, BASF, Cambrex, GlaxoSmithKline and Sun Pharmaceutical Industries
Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) — The “Active Pharmaceutical Ingredients: Global Markets” report has been added to …
Global Pharmaceuticals Contract Development & Manufacturing Market (2020 to 2025) – by Service, End-user and Geography
/PRNewswire/ — The “Global Pharmaceuticals Contract Development & Manufacturing Market (2020-2025) by Service, End User, Geography and the Impact of Covid-19…